Fakta om udbudet
Udbyder
Kungliga Tekniska högskolan
Vindere
(20.10.2018)
Irvine Scientific Ireland and UK
Newtown mount kennedy
Purchase of Transfectory Media and Feed4 for a High-throughput Midscale Protein Production in Chinese Hamster Ovary (CHO) Cells
Kungliga Tekniska högskolan
Voluntary ex ante transparency notice
Supplies
Directive 2014/24/EU
Section I: Contracting authority/entity
202100-3054
Roslagstullsbacken 21
Stockholm
10691
Sweden
Contact person: Kicki Holmberg
E-mail: hoki@kth.se
NUTS code: SE11
Internet address(es):
Main address: http://www.kth.se
Section II: Object
Purchase of Transfectory Media and Feed4 for a High-throughput Midscale Protein Production in Chinese Hamster Ovary (CHO) Cells
The Human Secretome project within the Wallenberg Center for Protein Research (WCPR) at the Royal Institute of Technology (KTH) has set up at high-throughput protein production pipeline to be able to produce a large number of recombinant proteins in CHO cells yearly. Now the production will change from small scale to midscale to produce higher amounts of each protein but still keep a high throughput flow. To be able to achieve this, the need for new culture media and feed media are necessary.
The Human Secretome project within WCPR at KTH has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319). It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins. Throughout the years we have established a robust production pipeline with this technology producing a large number of recombinant proteins in CHO cells and we will now shift the production from small scale (50 ml culture volume) to midscale (1,5 L culture volume) using the same host cells and vectors. To be able to cultivate the CHO cells and achieve the high amount of protein needed in a time efficient way, new culture media and feed media, that are not in the framework agreement are necessary. During the last year one of the researchers in the Protein Factory group has evaluated different protocols. Different culture media, feed media, shake flasks and transfection reagents
Section IV: Procedure
- The procurement falls outside the scope of application of the directive
The Human Secretome project within the WCPR at KTH has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319) developed by the Estonian company Icosagen Cell Factory OÜ. It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins and has been chosen after extensive testing of different expression systems. Today we have generated over 3 000 expression vectors that all are designed to work exclusively in Icosagen QMCF cells. Next step for our production pipeline is to produce higher amounts of each protein using these cells and vectors. During the last year one of the researchers in the Protein Factory group has evaluated different protocols. For example, different culture media, feed media, shake flasks and transfection reagents have been evaluated for the upscaled production. The optimized protocol now choosen for maintaining a high transfected cell density, viability, and to achieve the highest titers in the Icosagen system includes media produced and distributed by Irvine Scientific. This new cultivation protocol also works in a high-throughput way that is necessary for our production pipeline.
Because of the above stated reasons it is crucial for our upscaled production that we are able to buy this culture medium and feed medium from Irvine Scientific that are the manufacturer of these media and the only company that sells these products.
Section V: Award of contract/concession
IE9643654P
Newtown mount kennedy
Ireland
NUTS code: IE
Section VI: Complementary information
Stockholm
Sweden